EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Topical Drug Treatment of Rosacea in Switzerland: A Descriptive Study Using Swiss Claims Data

Tamino Zappalà, Alexander A Navarini, Carola A Huber, Christoph R Meier, Julia Spoendlin

Dermatology · 2025

DOI: 10.1159/000547337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology, 2025. Verfasst von Tamino Zappalà und 4 weiteren Autor:innen. Beteiligte Einrichtung: Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, S…. Hauptthemen laut MEDLINE: Rosacea, Metronidazole, Ivermectin, Brimonidine Tartrate. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Rosacea, a chronic inflammatory condition primarily affecting the skin of the face, has long been an area of interest for pharmaceutical advancements. In Switzerland, metronidazole was the only first-line topical rosacea medication (TRM), until brimonidine was licensed in 2014 and ivermectin in 2016. We aimed to evaluate the use of TRM between 2012 and 2023 in Switzerland.

Methods

We used healthcare claims data from the Swiss health insurance “Helsana Group” between 2012 and 2023 (study period). We quantified the monthly number of claims for each TRM per 10,000 insured persons, as well as the overall and annual prevalence of patients treated with TRM in Switzerland, stratified by age (≥/

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RosaceaMetronidazoleIvermectinBrimonidine TartrateDermatologic AgentsHumansFemaleMaleSwitzerlandMiddle AgedAdultAgedYoung AdultAdolescentAdministration, TopicalChildInsurance Claim ReviewAged, 80 and overAdministration, CutaneousPrevalence

Stichwörter der Autor:innen

Drug utilization studyHealthcare claims dataRosacea

Substanzen

MetronidazoleIvermectinBrimonidine TartrateDermatologic Agents

Autor:innen und Institutionen

  • Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland, tamino.zappala@unibas.ch.
  • Department of Dermatology, University Hospital Basel, Basel, Switzerland.
  • Department of Health Sciences, Helsana Group, Zurich, Switzerland.
  • Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
  • Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.

Zitieren

APA

Zappalà, T., Navarini, A. A., Huber, C. A., Meier, C. R., & Spoendlin, J. (2025). Topical Drug Treatment of Rosacea in Switzerland: A Descriptive Study Using Swiss Claims Data. Dermatology. https://doi.org/10.1159/000547337

Vancouver

Zappalà T, Navarini AA, Huber CA, Meier CR, Spoendlin J. Topical Drug Treatment of Rosacea in Switzerland: A Descriptive Study Using Swiss Claims Data. Dermatology. 2025. doi:10.1159/000547337

BibTeX
@article{Zappal2025,
  author = {Zappalà, Tamino and Navarini, Alexander A and Huber, Carola A and Meier, Christoph R and Spoendlin, Julia},
  title = {Topical Drug Treatment of Rosacea in Switzerland: A Descriptive Study Using Swiss Claims Data},
  journal = {Dermatology},
  year = {2025},
  doi = {10.1159/000547337}
}
Kostenlos starten →